
Roll Over Shakespeare: ChatGPT Is Here
Feb 21, 2025 10:00 AM Theater productions Doomers and McNeal tackle AI's impact on humanity and the creative process. Photo-Illustration:Sitting in Lincoln Center awaiting the curtain for Ayad Akhtar's McNeal —a much anticipated theater production starring Robert Downey Jr., with ChatGPT in a supporting role—I mused how playwrights have been dealing with the implications of AI for over a century. In 1920—well before Alan Turing devised his famous test and decades before the 1956 summer Dartmouth conference that gave artificial intelligence its name—a Czech playwright named Karel Čapek wrote R.U.R.—Rossum's Universal Robots. Not only was this the first time the word 'robot' was employed, but Čapek may qualify as the first AI doomer, since his play dramatized an android uprising that slaughtered all of humanity, save for a single soul.
Also on the boards in New York City this winter was a small black-box production called Doomers , a thinly veiled dramatization of the weekend where OpenAI's nonprofit board gave Sam Altman the boot, only to see him return after an employee rebellion.
Neither of these productions have the pizzazz of a splashy Broadway extravaganza—maybe later we'll buy tickets to a musical where Altman and Elon Musk have a dance-off—but both grapple with issues that reverberate in Silicon Valley conference rooms, Congressional hearings, and late-night drinking sessions at the annual NeurIPS conference. The artists behind these plays reveal a justifiable obsession with how superintelligent AI might affect—or take over—the human creative process.
Doomers is the work of Matthew Gasda, a playwright and screenwriter whose works zero in on the zeitgeist. His previous plays have included Dimes Square , about downtown hipsters, and Zoomers , whose characters are Gen-Z Brooklynites. Gasda tells me that when he read about the OpenAI Blip, he saw it as an opportunity to take on weightier fare than young New Yorkers. Altman's ejection and eventual restoration had a definite Shakespearian vibe. Gasda's two-act play on the topic features two separate casts, one depicting the Altman character's team in exile and the other focused on the board—including a genuine doomer seemingly based on AI theorist Eliezer Yudkowsky, and a greedy venture capitalist—as they realize that their coup is backfiring. Both groups do a lot of gabbing about the perils, promise, and morality of AI while they snipe about their predicaments.
Not surprisingly, they don't come up with anything like a solution. The first act ends with the dramatis personae taking shots of booze; in act two, the characters gobble mushrooms. When I mention to Gasda that it seems like his characters are ducking the consequences of building AI, he says that was intentional. 'If the play has a message, it's something like that,' he says. He adds that there's an even darker angle. 'There's a lot of suggestions that the fictional LLM is biding its time and manipulating the characters. It's up to audiences to decide whether that's total hokum or whether that's potentially real.' ( Doomers is still running in Brooklyn and will open in San Francisco in March.)
McNeal , a Broadway production with a movie star who famously played a character based on Elon Musk, is a more ambitious work, with flashing screens that project prompts and outputs as if AI is itself a character. Downey's Jacob McNeal, a narcissistic novelist and substance abuser, who gains the Nobel and loses his soul, winds up hooked on perhaps the most dangerous substance of all—the lure of instant virtuosity from a large language model.
Both playwrights are concerned about how deeply AI will become entangled in the writing process. In an interview in The Atlantic, Akhtar, a Pulitzer winner, says that hours of experimentation with LLMs helped him write a better play. He even gives ChatGPT the literal last word. 'It's a play about AI,' he explains. 'It stands to reason that I was able, over the course of many months, to finally get the AI to give me something that I could use in the play.' Meanwhile, while Gasda gave dramaturgy credits to ChatGPT and Claude in the Doomers program, he worries that AI will steal his words, speculating that to preserve their uniqueness, human writers might revert to paper to hide their work from content-hungry AI companies. He's also just finished a novel set in 2040 'about a writer who sold all of his works to AI and has nothing to do.'
Theater itself is probably the art least threatened by AI. Its essence consists of flesh-and-blood actors making words come to life on stage and forging a direct connection to an audience whose iPhones are (hopefully) deep in their pockets. As Akhtar said in the Atlantic interview, 'There is something irreducibly human about the theater, and … over time, it is going to continue to demonstrate its value in a world where virtuality is increasingly the norm.' I found McNeal 's ending particularly powerful, as we learn that our protagonist has perhaps fallen too far into the rabbit hole of ChatGPT. The performance ends on an apparently chatbot-created Shakespearean note that left us not only wondering how much of the protagonist's work was generated by AI but also whether the playwright had followed him into that same rabbit hole. I had the vertiginous feeling that reality itself had been bent by the newly fuzzy line between thought and algorithm. That's good theater.
And then the lights went on in Lincoln Center and I was back in the mundane physical world, only to discover that the bald head inches from my knees in the seat in front of me belonged to the ultimate real-life AI accelerationist, Marc Andreessen. Even ChatGPT couldn't have come up with a better plot twist.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
37 minutes ago
- Bloomberg
UK's AI Talent Is Envy of World and Needs Support, Nvidia CEO Says
Nvidia Corp. Chief Executive Officer Jensen Huang described the UK's artificial intelligence talent as the 'envy of the world,' specifically calling out its researchers, universities and startups. But he said the country needs to more infrastructure to unlock their potential. 'The UK is in a Goldilocks circumstance' with good conditions for AI companies to thrive, Huang said in a conversation with UK Prime Minister Keir Starmer at the start of London Tech Week on Monday. 'This is the largest AI ecosystem in the world without its own infrastructure.'
Yahoo
an hour ago
- Yahoo
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035" report has been added to world revenue for the AI-Enabled Drug Discovery and Clinical Trials Market will surpass US$3.00 billion in 2025 with strong revenue growth projected through to 2035. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new Drug Development Timelines and Cost Efficiency Driving Market GrowthKey drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth. However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these and Data Integration Challenges to Hamper Market GrowthWhile the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical Questions Answered How is the AI-enabled drug discovery and clinical trials market evolving? What is driving and restraining the AI-enabled drug discovery and clinical trials market? How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035? How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035? What will be the main driver for the overall market from 2025 to 2035? Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035? Who are the leading players and what are their prospects over the forecast period? What are the AI-enabled drug discovery and clinical trials projects for these leading companies? How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years? Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market? Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market? What are the best investment options for new product and service lines? What are the key prospects for moving companies into a new growth path and C-suite? Recent Developments On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets. On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs. On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes. Leading Companies Profiled AiCure Aitia Atomwise Inc. BenevolentAI Insilico Medicine PathAI, Inc. Recursion Saama Technologies Schroedinger, Inc. Tempus Inc. Key Topics Covered: 1 Report Overview1.1 Objectives of the Study1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market1.3 What This Report Delivers1.4 Why You Should Read This Report1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report for?1.7 Methodology1.8 Frequently Asked Questions (FAQs)1.9 Associated Reports1.10 About the Publisher2 Executive Summary3 Market Overview3.1 Key Findings3.2 Market Dynamics3.3 Impact Analysis3.3.1 Market Driving Factors3.3.1.1 Growing Focus on Personalized Medicine3.3.1.2 Advancements in Technology3.3.1.3 Growing Adoption of AI in Healthcare3.3.2 Market Restraining Factors3.3.2.1 Limited Data Availability and Quality3.3.2.2 Integration with Existing Infrastructure3.3.2.3 Concerns over Data Privacy and Security3.3.3 Market Opportunities3.3.3.1 Improved Patient Outcomes3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials3.3.3.3 Growing Collaborations and Partnerships3.4 Regulatory Framework3.5 Emerging Markets and Megatrends3.6 Porter's Five Forces Analysis3.7 PEST Analysis4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component4.1 Key Findings4.2 Component Segment: Market Attractiveness Index4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component4.4 Services4.4.1 Market Size by Region, 2025-2035 (US$ Million)4.4.2 Market Share by Region, 2025 & 2035 (%)4.5 Software Solutions5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application5.1 Key Findings5.2 Application Segment: Market Attractiveness Index5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application5.4 Clinical Trials5.4.1 Market Size by Region, 2025-2035 (US$ Million)5.4.2 Market Share by Region, 2025 & 2035 (%)5.5 Drug Design5.6 Data Aggregation and Analysis5.7 Drug Characterization5.8 Biomarker Research5.9 Others6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area6.1 Key Findings6.2 Therapeutic Area Segment: Market Attractiveness Index6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area6.4 Oncology6.4.1 Market Size by Region, 2025-2035 (US$ Million)6.4.2 Market Share by Region, 2025 & 2035 (%)6.5 Cardiovascular Diseases6.6 Infectious Diseases6.7 Neurodegenerative Diseases6.8 Metabolic Diseases6.9 Immunological Disorders6.10 Others7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users7.1 Key Findings7.2 End-users Segment: Market Attractiveness Index7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users7.4 Pharmaceutical & Biopharmaceutical Companies7.4.1 Market Size by Region, 2025-2035 (US$ Million)7.4.2 Market Share by Region, 2025 & 2035 (%)7.5 Contract Research Organizations (CROs)7.6 Academic Institutes and Research Centre8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region8.1 Key Findings8.2 Regional Market Size Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
HealthX Intelligence Conference 2025: The Premier Event for Healthcare Professionals Looking to Stay at the Cutting Edge of Technology (London, United Kingdom - September 17-18, 2025)
Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "HealthX Intelligence 2025" conference has been added to offering. The HealthX Intelligence 2025 conference is the premier event for healthcare professionals looking to stay at the cutting edge of technology. This two-day event features keynote speakers from top technology companies, hospitals & healthcare providers, pharmaceutical companies, investors, government agencies, and tech start-ups and the event will provide attendees with an immersive experience that explores how artificial intelligence, automation, machine learning and data analytics can be used to revolutionize healthcare delivery and patient care. From emerging technologies to successful implementations, this unique conference provides valuable insights into current trends in healthcare innovation. Participants will have the opportunity to explore various case studies, present their research findings, interact with experts in the field, and develop new collaborations. Additionally, they can learn about emerging technologies that could potentially revolutionize healthcare delivery systems in the years ahead. With HealthX Intelligence 2025, you'll have the knowledge and tools to ensure that your organization is well-prepared for what lies ahead in the world of healthcare. Join us to experience the possibilities for Healthcare Innovation in 2025 and beyond. KEY DISCUSSIONS WE'LL BE EXPLORING Digital Health Adoption & Implementation Strategies Artificial intelligence (AI) in health systems Machine learning and deep learning applications Health Data analytics and predictive modelling Utilizing Big Data for More Effective Population Health Management Cloud Technologies Automation and robotics in healthcare delivery Intelligent medical devices and wearable technology Electronic health records (EHR) and healthcare information systems Telemedicine and remote patient monitoring Clinical decision support systems Natural language processing (NLP) and voice recognition in healthcare Health data privacy and security in the age of automation Patient engagement and personalized medicine Healthcare process optimization and workflow automation Internet of Medical Things (IoMT) and connected healthcare Blockchain applications in healthcare Integrated Care Platforms Ethical and regulatory considerations in healthcare automation Digital Leadership Impact of Technology in Home Healthcare Who Should Attend: Healthcare Professionals Technology Experts Healthcare Providers Investors & Government Agencies Tech Startups Researchers in Artificial Intelligence and Automation Data Analysts & Analytics Specialists Clinical Managers & Administrators Wearable Technology Developers IT Professionals Working With Big Data Robotics Engineers Medical Device Manufacturers Entrepreneurs Pursuing Innovative Solutions in the Healthcare Industry For more information about this conference visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data